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Abstract
Canine vector-borne diseases (CVBDs) are of major socioeconomic importance worldwide. Although many studies
have provided insights into CVBDs, there has been limited exploration of fundamental molecular aspects of most
pathogens, their vectors, pathogen-host relationships and disease and drug resistance using advanced, ‘omic
technologies. The aim of the present article is to take a prospective view of the impact that next-generation,
‘omics technologies could have, with an emphasis on describing the principles of transcriptomic/genomic
sequencing as well as bioinformatic technologies and their implications in both fundamental and applied areas of
CVBD research. Tackling key biological questions employing these technologies will provide a ‘systems biology’
context and could lead to radically new intervention and management strategies against CVBDs.
Background
Although difficult to estimate, the impact of canine vec-
tor-borne diseases (CVBDs) to dog and human popula-
tions is substantial [1-3]. Particularly bacteria (e.g.,
species of Rickettsia, Ehrlichia and Borrelia), protists
(including species of Babesia, Leishmania and Trypano-
soma), nematodes (e.g., species of Dirofilaria and
Acanthocheilonema), and their vectors (including mos-
quitoes, fleas, ticks and/or sand flies) constitute major
components of the burden of CVBDs [2-4]. With a
changing global climate, in the absence of effective pre-
ventative approaches and new intervention strategies,
the disease burden linked to many neglected CVBDs is
likely to increase further [5]. In spite of advances made,
there are still major knowledge gaps in CVBDs. These
gaps exist mainly in the fundamental molecular biology,
epidemiology, ecology and population genetics of causa-
tive agents and their vectors, emerging drug resistance
issues as well as infection processes and virulence fac-
tors [1]. Moreover, substantial limitations in diagnosis
and intervention also represent critical obstacles to the
effective control of CVBDs. Although sustained research
and funding have contributed significantly to an
improved understanding of human vector-borne dis-
eases, such as malaria and trypanosomiasis, this is not
the case for many parasitic diseases, which are neglected
in terms of research and development [6]. A fundamen-
tal change is needed, particularly in relation to CVBDs.
The ‘omics era has brought about substantial pro-
spects for investigating some important pathogens and
their vectors, providing insights into their epidemiology,
ecology, evolution and cellular processes. Available gen-
omes are considered to represent crucial infrastructure
for elucidating novel avenues to tackle infectious dis-
eases. However, the relatively high cost and laborious
nature of molecular and biochemical research has some-
times been an impediment to progress. Revolutionary
developments in a range of ‘omic (e.g., genomic, proteo-
mic, metabolomic, glycomic and lipidomic) technologies
[7] now provide unprecedented opportunities to explore
CVBDs on a scale and at a rate that was unimaginable
just a couple of years ago, providing major opportunities
for addressing critically important areas of research for
the first time ever. Future research should harness such
technologies to address major knowledge gaps for
CVBDs. Elucidating the pathogens, their relationship
with their vector(s) and definitive hosts, the disease(s) as
well as the epidemiology and ecology of pathogens caus-
ing CVBDs will have substantial prospects to improve
the treatment, prevention and control of these parasites
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any medium, provided the original work is properly cited.in years to come. The intent of this presentation is not
to review the literature on CVBDs, rather to take a pro-
spective view of the impact that ‘omics technologies
could have on CVBD research. The emphasis has been
placed on describing the principles of transcriptomic/
genomic sequencing as well as bioinformatic technolo-
gies and their implications in both fundamental and
applied areas.
Transcriptomics, for example, is the molecular science
of examining, simultaneously, the transcription of all
genes at the level of the cell, tissue and/or whole organ-
ism, allowing inferences regarding cellular functions and
mechanisms. The ability to measure the transcription of
thousands of genes simultaneously has led to advances
in all biomedical fields, from understanding the basic
function in model organisms, such as the yeast, Sacchar-
omyces cerevisiae and the vinegar fly, Drosophila mela-
nogaster [8-10], to studying molecular processes or
mechanisms associated with growth, development and
reproduction, to the exploration of the mechanisms of
survival and drug-resistance. For more than a decade,
transcriptomes have been determined by sequencing
expressed sequence tags (ESTs), mainly using a conven-
tional (Sanger) approach [11,12], whereas levels of tran-
scription have been established quantitatively or semi-
quantitatively by real-time PCR [13] and/or cDNA
microarrays [14]. The use of such technologies has been
accompanied by an increasing demand for analytical
computer tools for the efficient annotation of nucleotide
sequence datasets, particularly within the framework of
large-scale EST projects [15]. With a substantial expan-
sion of nucleic acid sequencing has come the develop-
ment of algorithms for sequence assembly, analysis and
annotation, in the form of individual programs [16-18]
and integrated pipelines [19,20], some of which have
been accessible via the worldwide web [19,21,22]. How-
ever, the cost and time associated with conventional
sequencing and/or the design of customized analytical
tools have driven the search for alternative and
improved methods [23].
Next-generation sequencing technologies
There has been an explosion in next-generation
sequencing (NGS) technologies [24-27], which now
provide unprecedented opportunities to explore de
novo the transcriptomes and genomes of different spe-
cies and developmental stages of pathogens, their vec-
tors and/or their definitive hosts. Although introduced
recently, the capacity of such techniques to generate
millions to hundreds of millions of sequences in paral-
l e lh a sp l a c e dt h e ma tt h ef o r e f r o n to ft h em o l e c u l a r
research [28-30]. Currently available NGS sequencing
platforms include 454/Roche [24], Illumina/HiSeq [25]
and SOLiD [26].
The 454/Roche platform [24] employs a sequencing-
by-synthesis approach, by which cDNA is randomly
fragmented (by ‘nebulization’) into 500-1000 base pair
(bp) fragments. For the preparation of the library, an
adaptor is ligated to each end of these fragments, which
are then mixed with a population of agarose beads
whose surfaces anchor oligonucleotides complementary
to the 454-specific adapter sequence, such that each
bead is associated with a single fragment. Each of these
complexes is transferred into individual oil-water
micelles containing amplification reagents and is then
subjected to an emulsion PCR (emPCR) step, during
which ~10 million copies of each cDNA are produced
and bound to individual beads. In the sequencing phase,
the beads anchoring the cDNAs are deposited on a
pico-titre plate, together with other enzymes required
for the pyrophosphate sequencing reaction (i.e., ATP
sulfurylase and luciferase). The sequencing is carried out
by flowing sequencing reagents (nucleotide and buffers)
over a plate [31]. To date, the 454 sequencing technol-
ogy is a ‘long-read’ (100-600 bp) platform and is often
used for de novo genomic or transcriptomic studies.
The Illumina/HiSeq (formerly Solexa) technology has
features that differ significantly from the 454 approach
[25]. After fragmentation of cDNA sample into a shot-
gun library, Illumina-specific adaptors are ligated in
vitro to each cDNA template; one terminus of the tem-
plate is covalently attached to the surface of a glass slide
(or flow cell). Attached to the flow cell are primers com-
plementary to the other end of the template, which
bend the cDNAs to form bridge-like structures. During
the amplification step (bridge-PCR), clonal clusters, each
consisting of ~1000 amplicons, are generated and
immobilized to a single physical location on the slide.
Subsequently, the cDNAs are linearised, and the sequen-
cing reagents are directly added to the flow cell, with
four fluorescently labelled nucleotides. After the incor-
poration of individual fluorescent bases, the flow cell is
interrogated with a laser in several locations, which
results in several image acquisitions at the end of a sin-
gle synthesis cycle [31]. This technology is considered
ideal for re-sequencing projects, targeted sequencing,
single nucleotide polymorphism (SNP) analyses and
gene transcription studies.
The SOLiD platform employs the enzyme DNA
ligase, instead of a polymerase [26]. Briefly, after an
emPCR step, the adaptor sequences of the cDNA tem-
plates bind to complementary primers that are cova-
lently anchored to a glass slide. Subsequently, a set of
four fluorescently labelled di-probes (octamers of ran-
dom sequence, except known dinucleotides at the 3’-
terminus) is added to the sequencing reaction. In case
an octamer is complementary to the template, it is
ligated, and the two specific nucleotides can be called;
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dye is removed, so that other octamers can be ligated.
After multiple ligations (e.g., 7 ligations for a 35 bp
read), the newly synthesized cDNA is removed and the
primer is inactivated. This pro c e s si sr e p e a t e dm u l t i p l e
times from different starting points of the cDNA tem-
plates, so that each position is sequenced at least twice
(’two-base-calling’). Because of the short read-length,
the range of applications of the SOLiD system is con-
sidered similar to that of the Illumina technology and
includes (targeted) re-sequencing projects, SNP detec-
tion and gene transcription studies.
In the last years, a range of studies have demonstrated
the utility of NGS technologies for investigating, for
instance, aspects of the molecular biology, systematics
and population genetics of parasites [32-36]. In particu-
lar, 454 technology was used recently for the rapid de
novo sequencing of the transcriptomes of numerous
pathogens of humans and animals [33-41], yielding sub-
stantial datasets and providing a significant step forward.
The development of practical and efficient bioinformatic
tools has now become crucial for comprehensive ana-
lyses of such datasets.
Bioinformatic tools for the analysis of sequence
datasets
The application of NGS technologies has been accompa-
nied by an expansion of bioinformatic tools for the ana-
lysis of DNA, RNA and protein sequence datasets. This
expansion has resulted in the development of a number
of programs and/or integrated pipelines accessible via
the world-wide web (www) (e.g., [16,19,21,42,43]). The
principles, methods and protocols for the analysis of
sequence data, together with currently available bioin-
formatic tools and pipelines, have been reviewed [42].
In brief, following the acquisition of data, sequences
are firstly screened for repeats, contaminants and/or
adaptor sequences [42,44] and ‘clustered’ (= assembled)
into contiguous sequences (of maximum length; called
contigs) based on sequence similarity (see [42]). Long-
(e.g., generated by Sanger sequencing, 454 platform) and
short-reads (e.g., Illumina and SOLiD platforms) are
assembled using the algorithms ‘overlap-layout-consen-
sus’ [45] and ‘de Bruijn graph’ [46,47], respectively. For
the former algorithm [45], pair-wise overlaps among
reads are computed and stored in a graph; all graphs are
then used to compute a layout of reads and a consensus
sequence of contigs [21,48-53]. For the ‘de Bruijn graph’
[46,47], reads are fragmented into short segments,
denominated ‘k-mers’,w h e r e‘k’ represents the number
of nucleotides in each segment; overlaps between or
among k-mers are captured and stored in graphs, which
are subsequently used to generate the consensus
sequences [47,52-56].
Following assembly, the contigs and single reads (or
singletons) are compared, using different types of the
Basic Local Alignment Software Tool (BLAST; [57])
with known sequence data available in public databases,
in order to assign a predicted identity to each query
sequence if significant matches are found [42]. In addi-
tion, assembled nucleotide sequences are usually con-
ceptually translated into predicted proteins using
algorithms that identify protein-coding regions (ORFs)
from individual contigs [22,58,59]. Once peptides are
predicted, protein analyses, including amino acid
sequence comparisons with data available in public data-
bases, and known protein domains, are then undertaken
[17,42,60-63]. Public databases (accessible via www)
represent comprehensive collections of nucleotide and
amino acid sequences, where all publicly available
nucleotide sequences are stored and curated [64-66]; in
addition, each sequence is stored as a separate record
and linked to salient information, such as primary
source, references and predicted and/or experimentally
verified biological features. For transcriptomic datasets,
examples of databases include the UniGene [67] and the
Sequence Read Archive (SAR) [68]. In addition to these
general databases, there are various specialized collec-
tions of gene and protein information on particular
(model) organisms about which much is known. Exam-
ples include the databases for S. cerevisiae (yeast; http://
www.yeastgenome.org/) [69], D. melanogaster (vinegar
fly; http://flybase.org/[70], Mus musculus (mouse; http://
www.informatics.jax.org/) [71] and Caenorhabditis ele-
gans (free-living nematode; WormBase at http://www.
wormbase.org) [72,73].
A web-based bioinformatic pipeline (= ESTExplorer)
was established for the automated analysis and annota-
tion of nucleic acid datasets (both at the nucleotide and
amino acid levels) [19], and shown to substantially
accelerate and facilitate the analyses of sequences (gen-
erated using conventional Sanger sequencing) compared
with traditional database searches [20]. However,
sequences generated by NGS are significantly shorter
(454/Roche: ~400 bases; Illumina/SOLiD: ~60 bases)
than those determined by Sanger sequencing (0.8-1 kb),
which poses a significant challenge for assembly. In
addition, the data files generated by these technologies
are often gigabytes to terabytes (1 × 10
9 to 1 × 10
12
bytes) in size, substantially increasing the demands
placed on data transfer and storage, such that most
web-based interfaces are no longer suited for large-scale
analyses. In order to overcome this limitation, a recent
report [39] described the development of an integrated
bioinformatic workflow system for the analysis and
annotation of large sequence datasets produced by NGS,
in which the majority of the software was derived from
existing application tools (e.g., CAP3; [21]), available as
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using the Linux operation system, were incorporated
into pre-existing scripts (i.e., Perl, Python and Unix
shell), and can be downloaded http://research.vet.unim-
elb.edu.au/gasserlab/index.html[39] and readily executed,
also by scientists with limited bioinformatic expertise.
This workflow system has proved very useful for time-
efficient and accurate analyses of large-scale transcrip-
tomic datasets generated by NGS and for distilling bio-
logically meaningful information (such as predictions of
essential molecules) on the parasite, the vector or the
host under investigation.
Exciting prospects in both fundamental and
applied areas
Knowledge of the transcriptomes and proteomes of dif-
ferent developmental stages of a parasite, its vector and
its definitive host is central to gaining an enhanced
understanding of the molecular mechanisms that govern
essential biological, infection and disease processes and,
ultimately, could assist in identifying possible avenues
for the development of novel intervention strategies.
Accurate bioinformatic analyses of nucleic acid and pro-
tein sequence data (often by comparison with or infer-
ence from reference organisms) are crucial, in the
absence of information for the organism under study, in
providing biological meaningful molecular biological
information about CVBDs. Until recently, detailed bioin-
formatic analyses of such datasets have been restricted
largely to specialized laboratories with substantial com-
puter and software capacities. The development of flex-
ible and practical bioinformatic workflow systems is
beginning to provide scientists with user-friendly tools
for the analysis of massive datasets.
C u r r e n t l y ,d u et oal a c ko fc o m p l e t eg e n o m i c
sequences for many pathogens and vectors (and differ-
ent strains thereof) associated with CVBDs, newly gen-
erated sequence datasets need to be assembled de novo,
which means that pooled reads are assembled without a
bias towards known sequences [47]. Due to the amount
of RNA required for NGS (~5-10 μg) [74], transcrip-
tomes usually originate from numerous individuals,
potentially leading to an increased complexity of the
sequence data acquired (linked, for instance, to a biased
nucleotide content, single nucleotide polymorphisms
[SNPs] and other types of sequence variation) and
sometimes posing challenges for the data assembly. In
terms of complexity, computational and time require-
ments, de novo assemblies are much slower and more
computer-memory intensive than knowledge-based
(mapping) assemblies, in which reads are aligned and
assembled against an existing reference sequence (repre-
senting the same species or genetic variant) [18].
In addition, reliable de novo assemblies are highly
dependent upon the availability of long reads (>100
bases) and of high-coverage, paired-end sequence data
[75]. In previous studies, the complementary nature of
the 454 and Illumina sequencing platforms has allowed
the assembly of raw reads into large scaffolds without a
need for a reference sequence [76-78].
In the absence of reference genomes for agents and
vectors linked to CVBDs, accurate assembly of sequence
data is a crucial step in examining coding genes and,
ultimately, addressing biological questions regarding
gene and protein functions. Functions are initially pre-
dicted by ‘sequence annotation’ (= the process of gath-
ering all available information and relating it to the
sequence assembly both by experimental and computa-
tional means [79]. Accurate annotation is dependent on
the efficiency of the updates and curation. Presently,
open-source programs and databases routinely
employed for the bioinformatic analyses of sequence
data are available via multiple portals, thus requiring
significant efforts to maintain accurate and up-to-date
assembly and annotation pipelines [80]. In addition, the
rate at which public databases are updated and cor-
rected varies considerably. For instance, the Swiss-Prot
database http://au.expasy.org/sprot/ accepts corrections
from its user community, whereas GenBank http://
www.ncbi.nlm.nih.gov/genbank/ only accepts corrections
from the author of an entry [81], thus significantly
affecting the accuracy and speed with which new
sequences are annotated. In addition, some information-
management systems incorporate data from large-scale
projects, but often, the annotation of single records
from the literature is slow [82]. Given that, presently,
the annotation of sequence data for parasites and vec-
tors relies heavily on the use of bioinformatic
approaches and already annotated/curated sequence
data for a wide range of organisms, these aspects
deserve careful consideration.
The analyses and annotation of large-scale transcrip-
tomic, proteomic and genomic sequence datasets for
pathogens could be facilitated through the establishment
of a ‘reference’ website for CVBDs. Such a website could
provide regular releases of newly developed and vali-
dated bioinformatic pipelines for the analyses of
sequence datasets. It could also provide links to regu-
larly updated databases that are routinely employed for
the annotation of new sequences as well as a distinct,
high-quality database of curated functional annotations,
supported by experimental data published in peer-
reviewed, international publi c a t i o n s .I nt h ef u t u r e ,t h e
establishment of a ‘centralized’ resource to enable the
sharing and optimization of bioinformatic pipelines for
sequence processing and annotation and, more broadly,
to allow access to new sequence data, and experimental
protocols and relevant literature would be advantageous.
Gasser et al. Parasites & Vectors 2011, 4:53
http://www.parasitesandvectors.com/content/4/1/53
Page 4 of 10The annotation of peptides inferred from a dataset is
conducted by assigning predicted biological function/s
based on comparison with existing information available
for related organisms in public databases, including
InterPro http://www.ebi.ac.uk/interpro/, Gene Ontology,
http://www.geneontology.org/, OrthoMCL http://www.
orthomcl.org/, BRENDA http://www.brenda-enzymes.
org/. Using this approach, predictions for key groups of
molecules can be made regarding their fundamental
functional and essential roles in biological processes
[61]. Such groups include molecules linked to the phy-
siology of the nervous system [37], the formation of the
cuticle (arthropods and nematodes) [37,83], reproduc-
tion, development, signal transduction and/or pathogen
invasion and disease processes (e.g., proteases and pro-
tease inhibitors, protein kinases and phosphatases)
[36-39,84].
The bioinformatic prediction and prioritization of
novel drug targets involves ‘filtering’ [85,86] and usually
includes inferring targets based on key principles and
requirements [87-91]. First, target proteins should have
one or more essential roles in fundamental biological
processes of the pathogen and/or vector, such that the
disruption of the molecule or its gene will damage and/or
kill both or either and thus disrupt disease transmission
or disease itself, but not affect the host [90,92]. In the
absence of phenotypic data for many pathogens/vectors,
the prediction of drug target candidates in eukaryotic
pathogens/vectors can be assisted by using extensive
information on function and essentiality in a range of
eukaryotic organisms, including S. cerevisiae, D. melano-
gaster, C. elegans and M. musculus. This information can
be accessed via public databases, including FlyBase at
http://flybase.org/, WormBase at http://www.wormbase.
org, Mouse Genome Informatics at http://www.infor-
matics.jax.org/ and Saccharomyces Genome Database at
http://www.yeastgenome.org/) [39,89,93-95]. Since most
effective drugs achieve their activity by competing with
endogenous small molecules for a binding site on a target
protein [96], the amino acid sequences predicted from
essential genes should be screened for the presence of
relatively conserved ligand-binding domains [96,97]. Lists
of inhibitors, known based on experimental evidence, to
specifically bind to such domains, can be compiled. How-
ever, the predictions made are intended to support
hypothesis-driven or applied research and thus require
extensive experimental investigations. The main advan-
tage for a number of CVBD pathogens (e.g., Babesia and
Leishmania) over, for example, some parasitic helminths,
is that they can be propagated readily in vitro (e.g.,
[98,99]). This provides unique prospects to test gene
function(s) by double-stranded RNA interference, trans-
genesis and/or deletion studies as well as using small
molecular inhibitors (cf. [100-102]).
Based on recent evidence [103-105], guanosine tripho-
sphatases (GTPases), protein phosphatases and protein
kinases seem to represent attractive drug target candi-
dates for a range of pathogens, but have not yet been
examined on a genome-wide scale and in a systematic
manner for most CVBDs. Multiple cellular signaling
pathways function through the activity of small GTP-
binding proteins to regulate multiple biological processes,
such as transmembrane signal transduction, cytoskeletal
reorganization, gene expression, intracellular vesicle traf-
ficking, microtubule organization and nucleocytoplasmic
transport [106]. GTPases are small (~20-28 kDa), mono-
meric proteins belonging to six families (i.e., Ras, Rho,
Rab, Arf, Ran and Rad; [107]). These regulatory proteins
act as bi-molecular switches that cycle between two con-
formational states (i.e., GDP-bound ["inactive” state] and
GTP-bound ["active” state]) and hydrolyze GTP. In
humans, the aberrant regulation of GTPases is linked to
a number of dysfunctions, including neurological and
developmental disorders and cancer [108]. In addition,
intracellular pathogenic bacteria, such as Mycobacterium
tuberculosis, are known to target host GTPases to evade
host immune responses to facilitate the infection process
[109]. Such information has stimulated efforts to develop
novel therapeutic strategies to inhibit the function of
GTPases. For instance, treatments with farnesyltransfer-
ase inhibitors, to block the oncogenic properties of Ras
GTPases, have been shown to be effective in significantly
reducing the progression of various forms of cancer,
including carcinomas of the colon, pancreas and lung,
neurofibrosarcoma and chronic myelogenous leukaemia,
in experimental animals [110,111] and the migration and
organization of the cytoskeleton of human prostate can-
cer cells [112]. Although the overall structure of indivi-
dual small GTPases is conserved across eukaryotes, the
filtering of datasets for the organism of interest (i.e.,
pathogen and/or vector) allows the identification of sig-
nificant differences in sequence of GTPases between the
invertebrate and the definitive host. These differences
might be considered in future studies, aimed at assessing
the possibility of designing and synthesizing selective and
specific inhibitors against parasite GTPases. Homology
modelling [113,114], X-ray crystallography/nuclear mag-
netic resonance (NMR) and docking [115-120] studies
should assist in this process.
Selected protein kinases (PKs) are also potential drug
targets for a range of pathogens. PKs belong to a large
family of proteins regulating development, cell division,
differentiation and metabolism in many organisms; these
molecules are considered the second most important
group of drug targets after GPCRs [121,122]. The family
of PKs comprises cell surface receptors and non-recep-
tor or cytosolic kinases. Integrated genomic-bioinfor-
matic-chemoinformatic approaches have been employed
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tors as therapeutic agents [123-125]. For example, in
studies aimed at identifying novel inhibitors of a human
tyrosine kinase involved in the development and pro-
gression of chronic myelogenous leukemia, 15 com-
pounds were selected following in silico screening of a
database of 200,000 known inhibitors [124]. Of these
compounds, eight were shown to selectively inhibit the
growth of leukemia in vitro [124]. In another study,
novel and selective inhibitors of caseine kinase II (CK2)
were identified via in silico screening of a database con-
taining ~400,000 compounds, followed by in silico dock-
ing [125]. These examples indicate the advantages of
using computer-aided tools for the rational prediction
and design of drugs for subsequent in vitro and in vivo
efficacy testing [126]. Nonetheless, it is clear that any
compound shown to be efficacious must also be rigor-
ously tested for its safety (see [127]; http://www.ich.org/
cache/compo/276-254-1.html).
Because of the regulatory role that PKs play in a num-
ber of signaling pathways in the cell, interference with
their activity can result in the disruption of fundamental
homeostatic processes in parasites [105]. In the last
years, protein kinases have received particular attention
as drug targets in protists, such as species of Plasmo-
dium, Leishmania and Trypanosoma and helminths
[105]. For instance, particular inhibitors of pyrrole and
imidazopyridine cyclic guanosine monosphosphate-
dependent protein kinases of Leishmania major have
been shown to severely impair the growth of the pro-
mastigote forms of this protozoan parasite in vitro [128].
In some helminths, for example, PK inhibitors (i.e., tyr-
phostins AG1024 and AG538) have been shown to sig-
nificantly affect the survival and development of the
adult parasite through the blockage of glucose uptake
[122]. The inactivation of PKs with herbimicin A has
also been shown to interfere with mitosis, thus signifi-
cantly affecting the expression of proteins essential for
egg production in the worm [129]. Although the crystal
structures of PKs in many pathogens have not yet been
defined, progress has been made in the identification
and design of effective inhibitors based on homology
models for protein kinases from humans [105]. There is
evidence that the active sites of parasite PKs display
subtle differences compared with their human counter-
parts [105], which is considered promising for the devel-
opment of parasite-specific kinase inhibitors. However,
much more study is required to establish the potential
of PK inhibitors against pathogens causing CVBDs. This
is obviously a research area worth pursuing.
Concluding remarks
Vector-borne diseases, of which CVBDs represent a sub-
stantial component, represent ~17% of the burden of all
infectious diseases and have a major socioeconomic
impact worldwide [130]. In addition to their veterinary
importance, some CVBD-causing agents are of major
zoonotic importance. Although various studies have pro-
vided improved insights into the epidemiology of
CVBDs using molecular methods, there has been limited
study of fundamental molecular aspects of many patho-
gens, their vectors, pathogen-host relationships and dis-
ease as well as drug or insecticide resistance using some
of the advanced ‘omic technologies described here.
Tackling fundamental biological questions using these
technologies and understanding the relationship among
pathogens/vectors/environment will provide a ‘systems
biological context’ to better understand CVBDs and
their epidemiology and should lead to the design of
radically new intervention and management strategies
against these diseases.
For instance, from a fundamental perspective, genomic
sequencing and the definition of a wide range of genetic
markers for use in specific and sensitive diagnostic tools
could provide a solid foundation for addressing ques-
tions regarding the complex network of biological and
ecological factors involved in pathogen/host/environ-
ment interactions and the immunological idiosyncrasies
of receptive hosts in endemic regions as well as the role
of asymptomatic, chronically infected animals and those
infected with multiple pathogens [2]. In this context,
using well-defined genetic and transcriptomic tools, it
would be interesting to address the question as to
whether simultaneous infections with multiple vector-
borne pathogens (compared with a single infection)
induce synergistic and pronounced immunosuppression
in infected animals. Moreover, the application of -omics
tools could also assist in comprehensively studying the
complex intracellular pathways that are manipulated or
regulated by one or multiple pathogens (e.g., species of
Leishmania and Ehrlichia) to evade the immune
response of the host and significantly complicating the
progression and expression of disease in individual
patients (cf. [131,132]). It would also be very useful to
investigate the resistance and susceptibility of, for exam-
ples, particular dog breeds to CVBD-agents and their
vectors. For instance, a genomic comparison between
Ibizan hounds (which are resistant to leishmaniasis;
[133]) and other breeds, such as Boxers, as well as tran-
scriptomic/proteomic comparisons of the responses of
these dogs to infection and disease would be very inter-
esting. In a broader context, gaining improved insights
into the relationship between host genotype (through
genomic sequencing) and phenotype (degree of disease
expression) in response to particular CVBD-pathogens
and/or intervention approach (e.g., treatment/vaccina-
tion) would be particularly informative and could assist
in a deeper understanding the genetic basis of disease.
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spatial and temporal distribution of pathogens, vectors
and/or their hosts, as a result of climatic change and
global warming, might also be monitored using metage-
nomic approaches. These examples indicate clearly that
there are many exciting fundamental areas to tackle
using genomic, proteomic and immunomic tools in the
very near future.
From an applied perspective, clearly, the improved
prediction and prioritization of drug and vaccine targets
in CVBD pathogens or repellants against vectors is a
key area. NGS will provide the efficiency and depth-of-
coverage required to rapidly define de novo the com-
plete genomes of hosts, CVBD pathogens and their vec-
tors. Repertoires of drug or vaccine targets could be
inferred on a global scale. For example, the parasite
kinome (= the complete set of kinase genes in the gen-
ome) could represent a unique opportunity for the
design of pathogen-selective inhibitors [105] for subse-
quent validation by high throughput screening of para-
sites [134-137]. The combined use of genomic,
transcriptomic, proteomic and metabolomic datasets will
be crucial to identifying other groups of molecules
essential to the development and survival of a pathogen
for the design of novel classes of small molecular inhibi-
tors. Clearly, an integrated use of ‘omic technologies will
pave the way to a better understanding of the systems
biology of CVBDs on a scale never before possible, and,
hopefully, will provide golden opportunities for the
development of entirely new intervention strategies in
public-private partnerships.
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